Biotech company Pila Pharma, founded by former Novo Nordisk researcher Dorte X. Gram, recently received regulatory approval to conduct a 12-week clinical trial with the drug candidate XEN-D0501 in people with obesity.

The trial will investigate safety, tolerability, pharmacokinetics and efficacy at higher doses than previously studied, marking an important next step in the development of a potential new oral treatment for obesity. The trial is now ongoing.
XEN-D0501 differs from the dominant GLP-1 treatments by being a TRPV1 antagonist. Rather than targeting hormones such as GLP-1 and amylin, it acts on the TRPV1 receptor, which is involved in pain and inflammation.
In the trial, up to 46 participants will be treated, with the dose gradually increasing from 4 mg twice daily to a maximum of 16 mg twice daily, provided the individual participant tolerates the dose.